FDA approves name change for Takeda's PPI Kapidex
This article was originally published in Scrip
The US FDA has approved a name change for Takeda's protein pump inhibitor Kapidex (dexlansoprazole) to avoid confusion with two other medications – AstraZeneca's Casodex (bicalutamide), used to treat advanced prostate cancer, and Actavis' Kadian (morphine sulfate), used to treat pain. The regulators say that Takeda Pharmaceuticals North America will market its product under the name Dexilant beginning late April. The product is a single isomer version of lansoprazole.